BVS · Bioventus Inc.
$11.81
+0.33 (+2.87%)
At close · Jul 24
Market Cap
$985.71M
Shares
83.53M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Robert E. Claypoole | CEO | $4,299,108 |
| Mark Singleton | CFO | $1,897,062 |
| Anthony D’Adamio | General Counsel | $1,409,989 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert E. Claypoole | CEO | $6,379,010 |
| Mark Singleton | CFO | $2,087,676 |
| Anthony D’Adamio | Senior Vice President and General Counsel | $1,625,790 |
| Anthony Bihl | CEO | $21,302 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Anthony Bihl | CEO | $1,614,108 |
| Kenneth M. Reali | CEO | $1,319,972 |
| Mark Singleton | CFO | $1,058,233 |
| Anthony D’Adamio | Senior Vice President and General Counsel | $924,518 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kenneth M. Reali | CEO | $4,395,233 |
| Mark Singleton | CFO | $2,462,453 |
| John E. Nosenzo | Chief Commercial Officer | $2,276,548 |
| Alessandra Pavesio | Senior Vice President and Chief Science Officer | $2,044,416 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kenneth M. Reali | CEO | $12,618,883 |
| John E. Nosenzo | Chief Commercial Officer | $3,807,016 |
| Gregory O. Anglum | CFO | $3,718,800 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Kenneth M. Reali | CEO | $5,291,592 |
| John E. Nosenzo | Chief Commercial Officer | $907,276 |
| Gregory O. Anglum | CFO | $584,700 |
Key facts
CIK
1665988
CUSIP
09075A108
13F (30d)
16 filings
16 filers
Visit website
Investor relations